Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-ascending-dose ELND007 study in healthy elderly volunteers
NL-OMON34459Phase 1Active, not recruiting
- Sponsor
- Elan
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ELND007 in Alzheimer's disease (AD) (12 cohorts), sponsored by Elan. Primary endpoints: Safety and tolerability, Pharmacokinetics of ELND007 and 1 more. Started Jul 2010; status: active, not recruiting.
02
Drugs
ELND007
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON34459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34459.